PedAM
Pediatric Disease Annotations & Medicines
| Disease | thalassemia |
| Symptom | C0029456|osteoporosis |
| Sentences | 11 |
| PubMedID- 20976089 | The pathogenesis of osteoporosis in thalassaemia major (tm) is complicated and differs from the pathogenesis of bone deformities characteristically found in nontransfused patients who develop bone distortion mainly due to ineffective haemopoiesis and progressive marrow expansion 3. |
| PubMedID- 25002928 | Uncontrolled erythropoiesis and progressive marrow expansion are other causes of osteoporosis in thalassemia major and intermedia patients.osteoporosis is a side effect of iron toxicity on osteoblasts and also deferoxamine, an iron chelator which is used in these patients. |
| PubMedID- 22778734 | Subjects in low pubertal staging and short stature(<3% percentile) have significantly lower bone mass densities p < 0.001. conclusion.he prevalence of osteoporosis is high in patients with thalassemia major, possibly related to delayed puberty. |
| PubMedID- 23652868 | In a previous study aimed at comparing dxa and quantitative computed tomography (qct), mylona and colleagues observed a strong difference in the prevalence of osteopenia and osteoporosis in patients with β-thalassemia according to the technique used. |
| PubMedID- 25216685 | Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (trpv1) channels. |
| PubMedID- 26199898 | Local reduction of tgf-β in the bone marrow is a likely risk factor of osteoporosis in patients with thalassemia (26). |
| PubMedID- 25849944 | The reported frequency of osteoporosis, in thalassemia mayor patients, despite adequate transfusion and iron chelation therapy, varies from 13.6% to 50% with an additional 45% affected by osteopenia . |
| PubMedID- 20694183 | In a study by otrock et al,60 18 thalassemia patients with osteoporosis were given zol 4 mg iv every 3 months over a period of 12 months. |
| PubMedID- 22581647 | We conclude that circulating sclerostin is elevated in thalassemia patients with osteoporosis and correlated with their bmd, but it was not reduced post zoledronic acid administration. |
| PubMedID- 24575552 | osteoporosis in thalassemia major: an update and the i-cet 2013 recommendations for surveillance and treatment. |
| PubMedID- 22966867 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome. |
Page: 1